The quantitative Real-time PCR (qRT-PCR) was performed in all (n = 41) CML patients before imatinib treatment and conspicuous BCR-ABL gene expression was observed and all these CML patients were put on imatinib treatment (Fig. 2a,b). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.